Antimicrobial Agents and Chemotherapy · 2005 · 112 citations · 35 references
PharmacyPharmacokineticsPharmacologyPediatric Clinical PharmacologyPharmacokinetic ModelingPopulation PharmacokineticsPediatric Antimicrobial TherapyPediatric PharmacokineticsPediatric PharmacologyPharmacokinetics Of AntimicrobialsAntifungal Therapy In NeonatesInvasive Candidiasis TreatmentInvasive Fungal InfectionsPediatric Population PharmacokineticsPharmacokinetics In NeonatesPharmacokinetics Of Antifungal DrugsResidual Variability ModelingTotal Drug Concentrations
The pharmacokinetics of amphotericin B lipid complex (ABLC) were investigated in neonates with invasive candidiasis enrolled in a phase II multicenter trial. Sparse blood (153 samples; 1 to 9 per patient, 1 to 254 h after the dose) and random urine and cerebrospinal fluid (CSF) samples of 28 neonates (median weight [WT], 1.06 kg; range, 0.48 to 4.9 kg; median gestational age, 27 weeks; range, 24 to 41 weeks) were analyzed. Patients received intravenous ABLC at 2.5 (n = 15) or 5 (n = 13) mg/kg of body weight once a day over 1 or 2 h, respectively, for a median of 21 days (range, 4 to 47 days). Concentrations of amphotericin B were quantified as total drug by high-performance liquid chromatography. Blood data for time after dose (TAD) of <24 h fitted best to a one-compartment model with an additive-error model for residual variability, WT0.75 (where 0.75 is an exponent) as a covariate of clearance (CL), and WT as a covariate of volume of distribution (V). Prior amphotericin B, postnatal age, and gestational age did not further improve the model. The final model equations were CL (liters/h) = 0.399 x WT(0.75) (interindividual variability, 35%) and V (liters) = 10.5 x WT (interindividual variability, 43%). Noncompartmental analysis of pooled data with a TAD of >24 h revealed a terminal half-life of 395 h. Mean concentrations in the urine after 1, 2, and 3 weeks ranged from 0.082 to 0.430 microg/ml, and those in CSF ranged from undetectable to 0.074 microg/ml. The disposition of ABLC in neonates was similar to that observed in other age groups: weight was the only factor that influenced clearance. Based on these results and previously published safety and efficacy data, we recommend a daily dosage between 2.5 and 5.0 mg/kg for treatment of invasive Candida infections in neonates.
35
A Size Standard for Pharmacokinetics
Nicholas H. G. Holford · Clinical Pharmacokinetics · 1996 · 481 citations · Full text